RESEARCH PAPER
Emergence of HIV drug-resistant mutations in East Indian population after failure of first-line antiretroviral therapy
Submission date: 2016-10-05
Final revision date: 2017-11-23
Acceptance date: 2017-11-23
Publication date: 2017-12-06
HIV & AIDS Review 2017;16(4):258-264
KEYWORDS
antiretroviral therapyhuman immunodeficiency syndromeDRMsHIV-1resistancereverse transcriptaseprotease
TOPICS
ABSTRACT
Introduction: There are limited data on the failure of first-line antiretroviral therapy (ART) in resource- limited settings. In particular, there have not been any re-ports on first-line ART failure among patients in eastern India. We review data on the emergence of human immunodeficiency virus (HIV) drug resistance among indi-viduals with reported first-line ART failure.
Material and methods: Results of genotypic drug resistance testing were obtained from plasma samples of 44 patients who had presented with clinical or im-munological failure to treatment after at least six months of ART. Major drug re-sistance mutations (DRMs) associated with any of the three classes of antiretroviral (ARV) drugs, nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside re-verse transcriptase inhibitors (NNRTI), and protease inhibitors (PI) were seen in all pa-tients (100% prevalence).
Results: NRTI and NNRTI DRMs were encountered at a frequency of 34 (77.27%) and 15 (34.09%) amongst 44 patients, with M184V (34.09%), T215F (25.0%), and K219E (20.45%) being the most frequent among NRTI associated mutations, and Y188L (18.18%), K103N (6.81%), and A98G (6.81%) among NNRTI associated ones. PI DRMs were observed in 5/44 (11.3%) patients, with V82L, V82S, and I84V being the commonest.
Conclusions: These results present a high prevalence of DRMs among ART patients from eastern India with clinical or immunological failure. It is very important to enhance the access of ARV drugs so that their compliance could be improved and hence development of DRMs be minimised.
Material and methods: Results of genotypic drug resistance testing were obtained from plasma samples of 44 patients who had presented with clinical or im-munological failure to treatment after at least six months of ART. Major drug re-sistance mutations (DRMs) associated with any of the three classes of antiretroviral (ARV) drugs, nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside re-verse transcriptase inhibitors (NNRTI), and protease inhibitors (PI) were seen in all pa-tients (100% prevalence).
Results: NRTI and NNRTI DRMs were encountered at a frequency of 34 (77.27%) and 15 (34.09%) amongst 44 patients, with M184V (34.09%), T215F (25.0%), and K219E (20.45%) being the most frequent among NRTI associated mutations, and Y188L (18.18%), K103N (6.81%), and A98G (6.81%) among NNRTI associated ones. PI DRMs were observed in 5/44 (11.3%) patients, with V82L, V82S, and I84V being the commonest.
Conclusions: These results present a high prevalence of DRMs among ART patients from eastern India with clinical or immunological failure. It is very important to enhance the access of ARV drugs so that their compliance could be improved and hence development of DRMs be minimised.
REFERENCES (34)
1.
National AIDS Control Organization and National Institute of Medical Statistics (ICMR). India HIV Estimations 2015. Technical Report. Available at: http://www.naco.gov.in/upload/ 2015%20MSLNS/HSS/India%20HIV%20Estimations%202015.pdf (Accessed: 1.12.2015).
2.
Global Report. UNAIDS report on the global AIDS epidemic 2013. Joint United Nations Programme on HIV/AIDS (UNAIDS), 2013. Available at: http://www.unaids.org/sites/de... (Accessed: 1.01.2015).
3.
Jordan MR, Bennett DE, Wainberg MA, et al. Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004-2011. Clin Infect Dis 2012; 54 Suppl 4: S245-S249.
4.
National AIDS Control Organization, Department of AIDS Control. Anti Retroviral Therapy Guidelines for HIV-Infected Adults and Adolescents, May 2013. Available at: http://www.naco.gov.in/NACO/Ab... (Accessed: 1.01.2015).
5.
National AIDS Control Organization, Department of AIDS Control, Ministry of Health and Family Welfare. Government of India. Annual report 2014-15. Available at: http://www.naco.gov.in/upload/... (Accessed: 1.12.2015).
6.
Barth RE, Aitken SC, Tempelman H, et al. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients. Antivir Ther 2012; 17: 377-386.
7.
Aghokeng AF, Monleau M, Eymard-Duvernay S, et al. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-Saharan Africa and Southeast Asia. Clin Infect Dis 2014; 58: 99-109.
8.
Deshpande A, Karki S, Recordon-Pinson P, et al. Drug resistance mutations in HIV type 1 isolates from naive patients eligible for first line antiretroviral therapy in JJ Hospital, Mumbai, India. AIDS Res Hum Retroviruses 2011; 27: 1345-1347.
9.
Neogi U, Sahoo PN, De Costa A, et al. High viremia and low level of transmitted drug resistance in antiretroviral therapy-naive perinatally-infected children and adolescents with HIV-1 subtype C infection. BMC Infect Dis 2012; 12: 317.
10.
Sungkanuparph S, Kiertiburanakul S, Sukasem C, et al. Discrepancies between WHO 2009 and IAS-USA 2009 lists for determining the rate of transmitted HIV-1 drug resistance: a prospective study. J Acquir Immune Defic Syndr 2012; 59: e3-e5.
11.
Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23: 1127-1134.
12.
Leger P, Charles M, Severe P, et al. 5-year survival of patients with AIDS receiving antiretroviral therapy in Haiti. N Engl J Med 2009; 361: 828-829.
13.
Hamers R, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11: 750-759.
14.
Gupta R, Hill A, Sawyer AW, et al. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systemic review of clinical trials. Clin Infect Dis 2008; 47: 712-722.
15.
Deshpande A, Recordon-Pinson P, Deshmukh R. Molecular characterization of HIV type 1 isolates from untreated patients of Mumbai (Bombay), India and detection of rare resistance mutations. AIDS Res Hum Retroviruses 2004; 20: 1032-1035.
16.
Hira SK, Panchal K, Parmar PA, et al. High resistance to antiretroviral drugs: the Indian experience. Int J STD AIDS 2004; 15: 173-177.
17.
Lakshmi R, Ramesh K, Narayanan PR, et al. Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients. AIDS Res Hum Retroviruses 2009; 25: 1179-1185.
18.
Lakshmi R, Ramesh K, Hanna LE, et al. Emergence of drug resistant mutations after single dose nevirapine exposure in HIV-1 infected pregnant women in south India. Indian J Med Res 2010; 132: 509-512.
19.
NACO, HIV Testing policy and functioning of VCTC. Available at: www.nacoonline.org.
20.
NACO, HIV Testing manual: Laboratory Diagnosis, Biosafety and Quality Control. Available at: www.nacoonline.org.
21.
Eshleman H, Hackett J, Swanson P, et al. Performance of the Celera Diagnostics ViroSeq HIV-1 genotyping system for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J Clin Microbiol 2004; 42: 2711-2717.
22.
Stanford University HIV Drug Resistance Database IVDR). Available at: http://hivdb.stanford.edu.
23.
Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4: e4724.
24.
Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence weighting, position specific alignment through sequence weight matrix choice. Nucleic Acids Res 1994; 22: 4673-4680.
25.
Kumar S, Tamura K, Nei M. MEGA3: Integrated software for molecular evolutionary genetic analysis and sequence alignment. Brief Bioinform 2004; 5: 150-163.
26.
Kantor R, Katzenstein D. Drug resistance in non-subtype B HIV-1. J Clin Virol 2004; 29: 152-159.
27.
Khan IF, Vajpayee M, Prasad VS, et al. Genetic diversity of HIV type 1 subtype C env gene from India. AIDS Res Hum Retroviruses 2007; 23: 934-940.
28.
Gadkari DA, Moore D, Sheppard HW, et al. Transmission of genetically diverse strains of HIV-1 in Pune, India. Indian J Med Res 1998; 107: 1-9.
29.
Thorat SR, Chaturbhuj DN, Hingankar NK, et al. Surveillance of transmitted HIV type 1 drug resistance among HIV type 1-positive women attending an antenatal clinic in Kakinada, India. AIDS Res Hum Retroviruses 2011; 27: 1291-1297.
30.
Sinha S, Ahmad H, Shekhar RC, et al. Prevalence of HIV drug resistance mutations in HIV type 1 isolates in antiretroviral therapy naive population from northern India. Aids Res Treat 2012; 2012: 905823.
31.
Chaturbhuj DN, Hingankar NK, Srikantiah P, et al. Transmitted HIV drug resistance among HIV-infected voluntary counseling and testing centers (VCTC) clients in Mumbai, India. AIDS Res Hum Retroviruses 2010; 26: 927-932.
32.
Arora SK, Gupta S, Toor JS, et al. Drug resistance associated genotypic alterations in the pol gene of HIV type 1 isolates in ART-naive individuals in North India. AIDS Res Hum Retroviruses 2008; 24: 125-130.
33.
Lall M, Gupta RM, Sen S, et al. Profile of primary resistance in HIV-1- infected treatment-naive individuals from Western India. AIDS Res Hum Retroviruses 2008; 24: 987-990.
34.
Iqbal HS, Solomon SS, Madhavan V, et al. Primary HIV-1 drug resistance and polymorphic patterns among injecting drug users (IDUs) in Chennai, Southern India. J Int Assoc Physicians AIDS Care (Chic) 2009; 8: 323-327.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
